Slate Medicines

Executive Summary

Slate Medicines is a privately held biotechnology company headquartered in Cambridge, Massachusetts, focused on developing next-generation biologics that target the PACAP (pituitary adenylate cyclase-activating polypeptide) pathway for the treatment and prevention of migraine and other headache disorders. Founded in 2021, the company aims to address significant unmet needs in a large patient population, as current migraine therapies are often ineffective or poorly tolerated. By modulating the PACAP neuropeptide pathway, Slate's pipeline of monoclonal antibodies and other biologics seeks to provide more targeted and durable relief. The company's approach leverages deep expertise in neurobiology and antibody engineering, positioning it to potentially offer best-in-class or first-in-class options for migraine sufferers. As an early-stage private company, Slate Medicines has not yet disclosed clinical data or financing details, but its focus on a validated target and growing market interest in headache therapeutics suggests a promising trajectory.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead PACAP Antibody Program70% success
• Q1 2027Initiation of Phase 1 Clinical Trial for Migraine Prevention60% success
• Q3 2026Announcement of Strategic Partnership or Series A Financing50% success